Hui Wu1,2, Spyridon Siafis1, Tasnim Hamza3, Johannes Schneider-Thoma1, John M Davis4,5, Georgia Salanti3, Stefan Leucht1,6. 1. Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany. 2. Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 3. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. 4. Psychiatric Institute, University of Illinois at Chicago, Chicago, IL, USA. 5. Maryland Psychiatric Research Center, Baltimore, MD, USA. 6. Institute of Psychiatry, Psychology and Neuroscience, Department of Psychiatry, Department of Psychosis Studies, King's College London, London, UK.
Abstract
BACKGROUND: Weight gain is among the most important side-effects of antipsychotics. It is, however, unclear whether it is associated with antipsychotic doses. We aimed to fill this gap with a dose-response meta-analysis. METHODS: We searched multiple electronic databases (last update search June 2021) for all fixed-dose studies that investigated 16 second-generation antipsychotics and haloperidol in adults with acute exacerbation of schizophrenia or with negative symptoms. We estimated the dose-response curves by conducting random-effects dose-response meta-analyses. We used the restricted cubic spline to model the dose-response relationship. The primary outcome was mean weight gain in kg from baseline to endpoint, the secondary outcome was the number of patients with clinically important weight gain. FINDINGS: Ninety-seven studies with 333 dose arms (36 326 participants) provided data for meta-analyses. Most studies were short-term with median duration of 6 weeks (range 4 to 26 weeks). In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs. For most drugs, dose-response curves showed an initial dose-related increase in weight which plateaued at higher doses, while for others there was no plateau and some even had bell-shaped curves, meaning less weight gain to be associated with higher doses. INTERPRETATION: Second-generation antipsychotics do not only differ in their propensity to produce weight gain, but also in the shapes of their dose-response curves. This information is important for dosing decisions in clinical practice.
BACKGROUND: Weight gain is among the most important side-effects of antipsychotics. It is, however, unclear whether it is associated with antipsychotic doses. We aimed to fill this gap with a dose-response meta-analysis. METHODS: We searched multiple electronic databases (last update search June 2021) for all fixed-dose studies that investigated 16 second-generation antipsychotics and haloperidol in adults with acute exacerbation of schizophrenia or with negative symptoms. We estimated the dose-response curves by conducting random-effects dose-response meta-analyses. We used the restricted cubic spline to model the dose-response relationship. The primary outcome was mean weight gain in kg from baseline to endpoint, the secondary outcome was the number of patients with clinically important weight gain. FINDINGS: Ninety-seven studies with 333 dose arms (36 326 participants) provided data for meta-analyses. Most studies were short-term with median duration of 6 weeks (range 4 to 26 weeks). In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs. For most drugs, dose-response curves showed an initial dose-related increase in weight which plateaued at higher doses, while for others there was no plateau and some even had bell-shaped curves, meaning less weight gain to be associated with higher doses. INTERPRETATION: Second-generation antipsychotics do not only differ in their propensity to produce weight gain, but also in the shapes of their dose-response curves. This information is important for dosing decisions in clinical practice.
Authors: Marc De Hert; Johan Detraux; Ruud van Winkel; Weiping Yu; Christoph U Correll Journal: Nat Rev Endocrinol Date: 2011-10-18 Impact factor: 43.330
Authors: P Keck; A Buffenstein; J Ferguson; J Feighner; W Jaffe; E P Harrigan; M R Morrissey Journal: Psychopharmacology (Berl) Date: 1998-11 Impact factor: 4.530
Authors: Suresh Durgam; Andrew J Cutler; Kaifeng Lu; Raffaele Migliore; Adam Ruth; István Laszlovszky; György Németh; Herbert Y Meltzer Journal: J Clin Psychiatry Date: 2015-12 Impact factor: 4.384
Authors: Myrto T Samara; Loukia M Spineli; Toshi A Furukawa; Rolf R Engel; John M Davis; Georgia Salanti; Stefan Leucht Journal: Schizophr Res Date: 2013-11-18 Impact factor: 4.939
Authors: Stefan Leucht; Alessio Crippa; Spyridon Siafis; Maxine X Patel; Nicola Orsini; John M Davis Journal: Am J Psychiatry Date: 2019-12-16 Impact factor: 18.112